Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M4Xsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXndHo4UUN3ME2wMlYyOjN5IN88US=> M2GwcXNCVkeHUh?=
H4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTlUZg6UUN3ME2wMlY3OjhizszN NEnDT4NUSU6JRWK=
PA-1 M3[2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPmTWM2OD1yLki3NFk3KM7:TR?= NF3YTI5USU6JRWK=
NKM-1 NHuzN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMES5N|Eh|ryP M{TiOXNCVkeHUh?=
NEC8 NF3rRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwMkG1O|Ih|ryP MXPTRW5ITVJ?
EoL-1-cell NV3WS45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTpOoxKSzVyPUGuNlY4ODFizszN MYnTRW5ITVJ?
K5 NELKNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\XR2lEPTB;MT60NlA4OiEQvF2= MX;TRW5ITVJ?
QIMR-WIL NYLFRlZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXhTWM2OD1zLk[wPFU1KM7:TR?= MnPiV2FPT0WU
MOLT-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;GOY9PUUN3ME2xMlc5PjB2IN88US=> NX\tW5RFW0GQR1XS
CHP-212 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfGTWM2OD1zLkixN|Y6KM7:TR?= M1HuXHNCVkeHUh?=
CTB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMEKyOFYh|ryP M3Xs[XNCVkeHUh?=
MOLT-4 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPPSWdKSzVyPUKuN|I5PTNizszN NGPuSmdUSU6JRWK=
A101D Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:1TWM2OD1{LkO1NFEh|ryP M2PBe3NCVkeHUh?=
DOHH-2 NYP6TZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLMSnVZUUN3ME2yMlQzOjd7IN88US=> MnjGV2FPT0WU
ES4 NVjiSJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLxTWM2OD1{LkSzNVU2KM7:TR?= NIDsR4ZUSU6JRWK=
SW780 NEDOO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwNUC4PFMh|ryP NF3CTpNUSU6JRWK=
VA-ES-BJ MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDodVU4UUN3ME2yMlU1OTFizszN NW\MOWUzW0GQR1XS
RPMI-8866 M4DCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGyZ|FqUUN3ME2yMlU3OjF2IN88US=> NI\u[oNUSU6JRWK=
ML-2 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DUphKSzVyPUKuOVY2PzZizszN MWLTRW5ITVJ?
MSTO-211H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMTWM2OD1{LkW3OFUyKM7:TR?= NX;DRWh3W0GQR1XS
JVM-3 M2X1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJwNUmzNlQh|ryP Ml;DV2FPT0WU
A3-KAW NYjPXWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwNkG4NVgh|ryP NHy0XpJUSU6JRWK=
DK-MG NIT2bZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2yVnFKSzVyPUKuOlI1PzFizszN M3K3ZXNCVkeHUh?=
LNCaP-Clone-FGC M1Pybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HzeGlEPTB;Mj62OFMyQCEQvF2= M{TGSnNCVkeHUh?=
HT-144 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXldGwzUUN3ME2yMlY1PTd5IN88US=> NH3yTVNUSU6JRWK=
NB69 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DnbGlEPTB;Mj62OVM{PCEQvF2= M3H4fHNCVkeHUh?=
A172 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOcW45UUN3ME2yMlY4PTh6IN88US=> NUXCUVFLW0GQR1XS
RS4-11 M4LzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrlO21jUUN3ME2yMlczPDB5IN88US=> NH\QeFNUSU6JRWK=
DU-4475 M{DFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPHNXpzUUN3ME2yMlc6PTB{IN88US=> MV7TRW5ITVJ?
SJSA-1 NEf3WWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwOEK1OVYh|ryP NGDuTZpUSU6JRWK=
BV-173 M1rNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTJOIhKSzVyPUKuPFQ1OzlizszN MnnIV2FPT0WU
U-2-OS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwOUGwO{DPxE1? Mn7SV2FPT0WU
CHP-134 NILiVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XBbWlEPTB;Mj65N|g5OiEQvF2= NHLNbXpUSU6JRWK=
D-502MG MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfHTWM2OD1{Lkm3NVU1KM7:TR?= Moi1V2FPT0WU
KS-1 NWGwOVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojwTWM2OD1|LkCxOlI{KM7:TR?= NID4dpZUSU6JRWK=
A204 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TaSmlEPTB;Mz6wOVU5QCEQvF2= NEfVOI1USU6JRWK=
KGN NEHpN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq4foFoUUN3ME2zMlA5PDl4IN88US=> NIXvOIRUSU6JRWK=
NCI-H292 NFvuWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTPfJp4UUN3ME2zMlEzODJ6IN88US=> NFvSbnlUSU6JRWK=
CAKI-1 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3ESXdKSzVyPUOuNVI3QTRizszN MnrUV2FPT0WU
C2BBe1 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmx[HpqUUN3ME2zMlE4ODJ4IN88US=> MojZV2FPT0WU
NB10 NUX4O5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwMkC5OlYh|ryP NXX5foFRW0GQR1XS
MHH-NB-11 NXnDOVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQVY53UUN3ME2zMlI3QDJ5IN88US=> NELZcnNUSU6JRWK=
NCI-SNU-1 M{\WWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3OTWRKSzVyPUOuNlc5PDNizszN NGTnOHlUSU6JRWK=
HCT-116 M3WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIVpFKSzVyPUOuN|A{OzVizszN Moj5V2FPT0WU
G-401 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHewbHJKSzVyPUOuN|Y{OjJizszN MV3TRW5ITVJ?
MN-60 NUPqeYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwNESwPVIh|ryP MnnOV2FPT0WU
SW982 M1\FbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTTenc1UUN3ME2zMlUxQDR6IN88US=> M17NVHNCVkeHUh?=
RKO NETnT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwNUO5N|Yh|ryP MoTpV2FPT0WU
D-283MED NUHMdGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwNUe5PFYh|ryP Ml;rV2FPT0WU
LB996-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXHPFRQUUN3ME2zMlYzPTV6IN88US=> MoD6V2FPT0WU
A549 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPjelBKSzVyPUOuOlM2PTJizszN MkTuV2FPT0WU
LB2241-RCC NY\BWIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX34TpMxUUN3ME2zMlY2PzB6IN88US=> NXGxUGNlW0GQR1XS
SK-HEP-1 NFvwWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwN{SyPVch|ryP M4jOW3NCVkeHUh?=
G-402 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\oTWM2OD1|LkiwPFMzKM7:TR?= M2KzTHNCVkeHUh?=
GOTO M1P6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG0SoNKSzVyPUOuPFQ{OzNizszN MV\TRW5ITVJ?
LOXIMVI MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fIO2lEPTB;Mz64OVY4PSEQvF2= MXjTRW5ITVJ?
NH-12 NXf2WVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vQe2lEPTB;ND6wNVk2QSEQvF2= MlvuV2FPT0WU
CTV-1 NVG1coRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXPVHg6UUN3ME20MlA4QTd|IN88US=> NGDncWRUSU6JRWK=
CP50-MEL-B NYPaPWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRwMkSzPVIh|ryP NIL6eoZUSU6JRWK=
RH-18 NWjX[|RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHwTWM2OD12LkK3O|A3KM7:TR?= MmfVV2FPT0WU
NB17 M1rPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Q[WlEPTB;ND6zNVc3QCEQvF2= M4\pSnNCVkeHUh?=
A375 NFi5SFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPhRnFGUUN3ME20MlM{PTJ2IN88US=> NF3rXI5USU6JRWK=
IST-MES1 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn5ZmlKSzVyPUSuOFE1OTFizszN M2HzO3NCVkeHUh?=
MZ2-MEL MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRwNUCxOVUh|ryP NVm0d5hkW0GQR1XS
CAL-54 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwNUOwNVkh|ryP MYrTRW5ITVJ?
NCI-H28 NYLkcml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu2[WpKSzVyPUSuOlI4OTdizszN Mm\HV2FPT0WU
D-247MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PUV2lEPTB;ND63OVA4OiEQvF2= NVjXfYppW0GQR1XS
NCI-H460 NFjxcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwOUGxNlch|ryP Mn3aV2FPT0WU
MCF7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TXe2lEPTB;NT60OFI1PCEQvF2= MnHlV2FPT0WU
697 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\RTo1KSzVyPUWuOFQ2PSEQvF2= NVzKW|NpW0GQR1XS
ONS-76 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\J[2lEPTB;NT61O|AxQSEQvF2= MVTTRW5ITVJ?
C32 NWnWWGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTVwNkCwNlkh|ryP MXrTRW5ITVJ?
OS-RC-2 NGjmVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1RWlEPTB;NT63N|g5PyEQvF2= M{H3[nNCVkeHUh?=
MEL-HO NF\kTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJXmlEPTB;NT64OVY3PyEQvF2= NHLKRnBUSU6JRWK=
LoVo M1TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\3dXlvUUN3ME22MlAyPjJ2IN88US=> MojvV2FPT0WU
AGS M2e2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjQUJNKSzVyPU[uNVQ5OjhizszN M17lcXNCVkeHUh?=
GI-ME-N NV;tcHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nMcWlEPTB;Nj6yNlQzOSEQvF2= NGfX[Y1USU6JRWK=
H-EMC-SS MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZwM{i2JO69VQ>? MmLUV2FPT0WU
RVH-421 M{LSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwNEK0Nlgh|ryP MnXiV2FPT0WU
SW954 NECzRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZwNUW1O|Ih|ryP NYnz[GJrW0GQR1XS
NB5 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PZWmlEPTB;Nj61OlE5OyEQvF2= NWfkVnAxW0GQR1XS
NCI-H2122 NXTJOWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTZwNUi3PVMh|ryP NG\6eGpUSU6JRWK=
AM-38 NGKye4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZwN{W2N|kh|ryP Mn\HV2FPT0WU
KNS-81-FD NFz5WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDtbWNPUUN3ME22Mlc3PDl2IN88US=> M{m2TXNCVkeHUh?=
LS-513 M{XBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS3TWM2OD14Lke5NFI3KM7:TR?= MXjTRW5ITVJ?
A427 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3OcVBKSzVyPU[uPFc5OjlizszN M2nG[3NCVkeHUh?=
WM-115 NXKzbVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnTSWlKSzVyPU[uPVMzOyEQvF2= NXvpdVRsW0GQR1XS
COLO-829 M{nneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\GTWM2OD15LkK0NVg5KM7:TR?= MnW2V2FPT0WU
NCI-H1650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTdwM{myNlgh|ryP MVHTRW5ITVJ?
NCI-H358 NUDT[5hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW1NnpKSzVyPUeuOFQ5PzlizszN NInmVJVUSU6JRWK=
HT-1080 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jj[GlEPTB;Nz60PFI2PCEQvF2= MVrTRW5ITVJ?
HCC2218 M1f5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;5W2lEPTB;Nz62Nlk4KM7:TR?= M3XrOnNCVkeHUh?=
NCI-H661 NUHPXZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml74TWM2OD15Lki3NFY6KM7:TR?= NUL1OJdFW0GQR1XS
KM-H2 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvnTWM2OD15Lki4Olk1KM7:TR?= NYq3eWI6W0GQR1XS
RPMI-2650 M33OZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwOUS0NVQh|ryP M164cXNCVkeHUh?=
NCI-H226 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPkTWM2OD16LkKxNVIzKM7:TR?= MUjTRW5ITVJ?
MKN45 NH7vR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIVYtKSzVyPUiuNlY3ODJizszN M{DIXnNCVkeHUh?=
D-392MG NWGx[Gd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHqTWM2OD16LkWyO|IzKM7:TR?= MVzTRW5ITVJ?
RCC10RGB NFf0XpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[5TWM2OD16Lki2Olk2KM7:TR?= MWHTRW5ITVJ?
CAL-51 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFTWM2OD17LkGwNlUyKM7:TR?= MWrTRW5ITVJ?
COLO-678 M1X2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvMTWM2OD17LkOyPFEyKM7:TR?= M2\0TnNCVkeHUh?=
SK-MEL-24 NIjrcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HYXmlEPTB;OT61OVg2PiEQvF2= NGHDfIVUSU6JRWK=
SK-MEL-30 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDOc2oxUUN3ME25Mlk1PDd4IN88US=> NFLLdIVUSU6JRWK=
MMAC-SF MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPvTWM2OD1zMD6zPVYyKM7:TR?= M{DZfnNCVkeHUh?=
NTERA-S-cl-D1 NIDXeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2[ok6UUN3ME2xNE43PTB6IN88US=> MVHTRW5ITVJ?
NB12 NGHGbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKwTWM2OD1zMT61NFMh|ryP NWnEfGx[W0GQR1XS
UACC-257 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH63UGFKSzVyPUGxMlg3QTVizszN NXLKWldHW0GQR1XS
LAN-6 NIPRdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFzLkm5Nlgh|ryP MlriV2FPT0WU
SW1573 NUX1V4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfaTWM2OD1zMj6zNFg3KM7:TR?= NUDJcm96W0GQR1XS
NMC-G1 NWrK[5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF{LkSxO|Uh|ryP M17vNXNCVkeHUh?=
SHP-77 NYf1dlF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wdnBKSzVyPUGyMlU2PzRizszN M1nuVnNCVkeHUh?=
IGROV-1 NHfDenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j4RWlEPTB;MUKuOlU4OyEQvF2= NHP3ZVhUSU6JRWK=
22RV1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDxTWM2OD1zMj64NFU6KM7:TR?= MmTLV2FPT0WU
SK-MEL-3 NUHSV3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n1SWlEPTB;MUOuN|k4OyEQvF2= MoK2V2FPT0WU
NCI-H1563 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37O[GlEPTB;MUOuOFIxOiEQvF2= M3X6dnNCVkeHUh?=
IGR-1 NGTOS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P0emlEPTB;MUSuNFM1PyEQvF2= NIHDOJJUSU6JRWK=
EW-3 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDhdYlKSzVyPUG0MlE3OzlizszN NYTJbGZYW0GQR1XS
JEG-3 NVr3N29CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xcJFKSzVyPUG0MlQ6PTNizszN NWf5WWFoW0GQR1XS
ES3 M2LWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2Lk[1OlIh|ryP MVzTRW5ITVJ?
MDA-MB-175-VII NFv6eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2XW1DUUN3ME2xOE44OTFzIN88US=> NHPqVnVUSU6JRWK=
P30-OHK MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjmTWM2OD1zNT6wOFk3KM7:TR?= MWDTRW5ITVJ?
GP5d NG\ZV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zMRmlEPTB;MUWuNVQ3PiEQvF2= M2r1cnNCVkeHUh?=
HMV-II NUXLVWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzIOXlKSzVyPUG1MlM{OzNizszN M{nvS3NCVkeHUh?=
COLO-679 NFTjbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\oTVJKSzVyPUG1MlUxOSEQvF2= NF;vcotUSU6JRWK=
JAR MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SxeWlEPTB;MUWuO|IxPSEQvF2= MV;TRW5ITVJ?
NCI-H1666 NIrtV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED3blVKSzVyPUG1Mlk{QTlizszN MV7TRW5ITVJ?
SW48 NXP1SGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXWcmdKSzVyPUG1Mlk2OTZizszN NV;YbWJEW0GQR1XS
NCI-H720 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq0cXVlUUN3ME2xOU46QTh7IN88US=> M2LSUnNCVkeHUh?=
HT-1197 M4i3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF4LkCzOVIh|ryP MoL6V2FPT0WU
HL-60 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3mTWM2OD1zNj6wN|g1KM7:TR?= NWLJOnRGW0GQR1XS
BEN MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK1VWZKSzVyPUG2MlU3OzhizszN MXXTRW5ITVJ?
HAL-01 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HCUGlEPTB;MU[uPFkxQSEQvF2= NH\rO|dUSU6JRWK=
SW900 NGrLe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF4LkmxN|Ih|ryP NUDxTppwW0GQR1XS
SBC-1 NHPLZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjIUoRKSzVyPUG3MlU1OjlizszN NX\rPZVXW0GQR1XS
SH-4 M3rUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF5LkW4OFEh|ryP MULTRW5ITVJ?
UACC-62 M33RPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMTWlEPTB;MUeuO|Y{PyEQvF2= M3\wS3NCVkeHUh?=
BHT-101 M4nQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF7Lki3NFUh|ryP M{X1VXNCVkeHUh?=
DB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLMOJZwUUN3ME2yNU42PjR7IN88US=> M2\EbHNCVkeHUh?=
SK-MEL-1 M2L0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\YTWM2OD1{MT61PFczKM7:TR?= NUDmRphPW0GQR1XS
NCI-H747 NXq3T|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ{LkezO|kh|ryP M2DaWnNCVkeHUh?=
SK-LU-1 NWO3TZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHQNI8yUUN3ME2yN{4{PTJ2IN88US=> MnuxV2FPT0WU
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTQS|NGUUN3ME2yN{41QTR4IN88US=> NFrXc49USU6JRWK=
LXF-289 M1;Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ|LkexOEDPxE1? NH7weJVUSU6JRWK=
HCC1954 M3nBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jMcGlEPTB;MkSuPFg1PCEQvF2= MXzTRW5ITVJ?
Ramos-2G6-4C10 NIr3b3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ4LkS5PFEh|ryP NFX2OmVUSU6JRWK=
DBTRG-05MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzxOWUyUUN3ME2yOk43PDh6IN88US=> Mmm1V2FPT0WU
NCI-H2052 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Md2lEPTB;MkeuOVY5PCEQvF2= NIW2WVZUSU6JRWK=
RMG-I MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ7LkSxN|kh|ryP Ml;YV2FPT0WU
H9 M3;wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNzLkOwNFgh|ryP NVLHbpF2W0GQR1XS
GR-ST NE\CO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTN{LkS0OVMh|ryP NUjWeW1jW0GQR1XS
Mo-T M1HvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHoZoNKSzVyPUOyMlUxPDZizszN M3HKSHNCVkeHUh?=
SW1088 M1r2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLHTWM2OD1|Mj65PFAyKM7:TR?= MUnTRW5ITVJ?
LB2518-MEL MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\VN4hDUUN3ME2zN{4xPzl5IN88US=> NFnUO3RUSU6JRWK=
NCI-H82 NWHPdZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN|LkG2OlEh|ryP MX7TRW5ITVJ?
LAMA-84 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6PGlEPTB;M{SuOlA4OyEQvF2= MYTTRW5ITVJ?
KYSE-450 NUDLU3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN2Lk[3O|Yh|ryP MXLTRW5ITVJ?
LU-99A NWD0OY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN3LkCwNFch|ryP NGPEPHdUSU6JRWK=
BE-13 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjMeHlbUUN3ME2zOU43PTR3IN88US=> NXzxR4pIW0GQR1XS
GAK Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70dVBKSzVyPUO1MlY6PSEQvF2= NXrtdmZRW0GQR1XS
NCI-H1573 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M373S2lEPTB;M{WuPFgyQCEQvF2= NYqzZYZRW0GQR1XS
AsPC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm5Vm9WUUN3ME2zOk4yPTJ5IN88US=> NVPCPVZTW0GQR1XS
HDLM-2 M3PXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfleotKSzVyPUO2MlMyPiEQvF2= MWrTRW5ITVJ?
NCI-H441 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLLZlQyUUN3ME2zO{4xPjlzIN88US=> NULJd4dpW0GQR1XS
CAL-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN5LkeyN|Eh|ryP MXvTRW5ITVJ?
OVCAR-3 M1Pw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLVemZ1UUN3ME2zPU4{OThzIN88US=> MWDTRW5ITVJ?
RPMI-8226 M2\xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFZmlEPTB;M{muOVk5KM7:TR?= M1zYNnNCVkeHUh?=
EFO-21 NWTz[Yo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\rfpBKSzVyPUSwMlU5OTRizszN MkDIV2FPT0WU
SNU-C2B NFzWS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W3TmlEPTB;NEGuOVA5PCEQvF2= NWj2PINMW0GQR1XS
VM-CUB-1 M1fSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjKdoMzUUN3ME20N{45ODN5IN88US=> M{f2eXNCVkeHUh?=
NCI-H2087 M32z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2[nZkUUN3ME20OU4xOjN|IN88US=> MoPMV2FPT0WU
EW-16 NY\OOWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO1ZohqUUN3ME20Ok4{OTN5IN88US=> MoLwV2FPT0WU
SK-N-AS NGnycG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT0SndKSzVyPUS2MlcyPjdizszN Mm\KV2FPT0WU
COR-L105 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR4Lki4OVch|ryP M1jxWHNCVkeHUh?=
DEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR6LkC0Nlkh|ryP MVPTRW5ITVJ?
JVM-2 NIDse|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrITWM2OD12OD6wOVU5KM7:TR?= MlTDV2FPT0WU
KARPAS-45 NYPjWJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXXTWM2OD12OT60OVM5KM7:TR?= NUTPZ2VyW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID